Daniela Gramaglia

Daniela Gramaglia

Auto-generated profile, based on publicly available information

Daniela Gramaglia

Department of Clinical Molecular Oncology, Institute for Cancer Research (IRCC), University of Turin Med. School, Candiolo, Italy

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 December 1997 in Oncogene
Verified
Journal Article
Closed access
ABAlberto Bardelli
Alberto Bardelli
PLPaola Longati
Paola Longati
DGDaniela Gramaglia
Daniela Gramaglia
MSMaria C Stella
Maria C Stella
PCPaolo m Comoglio
Paolo m Comoglio

4 September 2006 in Oncogene
Verified
Journal Article
Closed access
PDF file
Andrea RasolaAndrea Rasola
Andrea Rasola
MFM Fassetta
M Fassetta
FBF De Bacco
F De Bacco
LDL D'Alessandro
L D'Alessandro
DGD Gramaglia
D Gramaglia
PCPaolo m Comoglio
Paolo m Comoglio

1 January 2001 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
Andrea RasolaAndrea Rasola
Andrea Rasola
DGDaniela Gramaglia
Daniela Gramaglia
CBCarla Boccaccio
Carla Boccaccio
PCPaolo m Comoglio
Paolo m Comoglio
The HIV-1 nef gene, essential for AIDS pathogenesis, encodes a 27-kDa protein (Nef) whose biochemical and biological functions are unclear. It has been suggested that Nef expression contributes to the T cell depletion observed during the disease by promoting their apoptosis. We report that in CD4+ human lymphoblastoid cell lines transfected with the nef cDNA obtained from three different HIV-1 strains, expression of the Nef protein enhances and accelerates the response to four unrelated apoptotic agents (staurosporine, anisomycin, camptothecin, and etoposide) but not to an anti-Fas agonist Ab. Nef reduces the expression of the anti-apoptotic proteins Bcl-2 and Bcl-XL and induces a striking enhancement of apoptotic hallmarks, including mitochondrial depolarization, exposure of phosphatidylserine on the cell surface, activation of caspase-3, and cleavage of the caspase target poly(ADP-ribose) polymerase. Interestingly, the peptide Z-Val-Ala-DL-Asp-fluoromethylketone (a broad-spectrum caspase inhibitor) reduces, but does not abolish, phosphatidylserine exposure, suggesting that Nef also activates a caspase-independent apoptotic pathway. Surprisingly, Nef expression increases DNA degradation but without causing oligonucleosomal fragmentation. An increased apoptotic response and down-modulation of Bcl-2/Bcl-XL following Nef expression are observed also in NIH-3T3 fibroblasts. These data show that Nef enhances programmed cell death in different cell types by affecting multiple critical components of the apoptotic machinery independently from the Fas pathway.

24 November 1998 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
ABAlberto Bardelli
Alberto Bardelli
PLPaola Longati
Paola Longati
DGDaniela Gramaglia
Daniela Gramaglia
CBCristina Basilico
Cristina Basilico
LTLuca Tamagnone
Luca Tamagnone
PCPaolo m Comoglio
Paolo m Comoglio
The assumption that genes encoding tyrosine kinase receptors could play a role in human cancers has been confirmed by the identification of oncogenic mutations in the kinase domain of RET and KIT . Recently, homologous residues were found mutated in MET , in papillary renal carcinomas (PRCs). The link coupling these genetic lesions to cellular transformation is still unclear. MET PRC mutations result in increased kinase activity and—in some instances, i.e., M1250T substitution—in changes in substrate specificity. A direct correlation occurs between the transforming potential of MET PRC mutants and their ability to constitutively associate with signal transducers through two phosphorylated tyrosines (Y 1349 VHVNATY 1356 VNV) located in the receptor tail. Substitution of these “docking tyrosines” with phenylalanines leaves unaffected the altered properties of the kinase but abrogates transformation and invasiveness in vitro . Uncoupling the receptor from signal transducers with a tyrosine-phosphorylated peptide derivative (Y p VNV) inhibits invasive growth induced by MET PRC mutants. These data indicate that constitutive receptor coupling to downstream signal transducers is a key mechanism in neoplastic transformation driven by mutated MET and suggest a therapeutic strategy to target neoplastic diseases associated with this oncogene.

1 September 2000 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
SCSantina Cutrupi
Santina Cutrupi
Gianluca BaldanziGianluca Baldanzi
Gianluca Baldanzi
DGDaniela Gramaglia
Daniela Gramaglia
AMAntonella Maffè
Antonella Maffè
DSDick Schaap
Dick Schaap
AGAndrea Graziani
Andrea Graziani
Diacylglycerol kinases are involved in cell signaling, either as regulators of diacylglycerol levels or as intracellular signal‐generating enzymes. However, neither their role in signal transduction nor their biochemical regulation has been elucidated. Hepatocyte growth factor (HGF), upon binding to its tyrosine kinase receptor, activates multiple signaling pathways stimulating cell motility, scattering, proliferation and branching morphogenesis. Herein we demonstrate that: (i) the enzymatic activity of α‐diacylglycerol kinase (αDgk) is stimulated by HGF in epithelial, endothelial and αDgk‐transfected COS cells; (ii) cellular expression of an αDgk kinase‐defective mutant inhibits activation of endogenous αDgk acting as dominant negative; (iii) specific inhibition of αDgk prevents HGF‐induced cell movement of endothelial cells; (iv) HGF induces the association of αDgk in a complex with Src, whose tyrosine kinase activity is required for αDgk activation by HGF; (v) Src wild type stimulates αDgk activity in vitro ; and (vi) αDgk can be tyrosine phosphorylated in intact cells.

22 July 1999 in Oncogene
Verified
Journal Article
Open access
PDF file
EVElisa Vigna
Elisa Vigna
DGDaniela Gramaglia
Daniela Gramaglia
PLPaola Longati
Paola Longati
ABAlberto Bardelli
Alberto Bardelli
PCPaolo m Comoglio
Paolo m Comoglio
TPR-MET, a transforming counterpart of the c-MET proto-oncogene detected in experimental and human cancer, results from fusion of the MET kinase domain with a dimerization motif encoded by TPR. In this rearrangement the exons encoding the Met extracellular, transmembrane and juxtamembrane domains are lost. The juxtamembrane domain has been suggested to be a regulatory region endowed with negative feedback control. To understand whether its absence is critical for the generation of the Tpr-Met transforming potential, we produced a chimeric molecule (Tpr-juxtaMet) with a conserved juxtamembrane domain. The presence of the domain (aa 962–1009) strongly inhibited Tpr-Met dependent cell transformation. Cell proliferation, anchorage-independent growth, motility and invasion were also impaired. The enzymatic behavior of Tpr-Met and Tpr-juxtaMet was the same, while Tpr-juxtaMet ability to associate cytoplasmic signal transducers and to elicit downstream signaling was severely impaired. These data indicate that the presence of the juxtamembrane domain counterbalances the Tpr-Met transforming potential and therefore the loss of the exon encoding the juxtamembrane domain is crucial in the generation of the active TPR-MET oncogene.